Publications by authors named "Gabriella F Rodriguez"
Article Synopsis
- Tucatinib is a tyrosine kinase inhibitor used to treat HER2-positive breast and colorectal cancer, and its use is expanding in combination with T-DM1 for advanced cases.
- A case report describes a 66-year-old woman who developed widespread telangiectasias after starting treatment with tucatinib and T-DM1 for metastatic HER2-positive breast cancer.
- The telangiectasias improved after stopping the treatment and gradually lessened after electrocautery, suggesting that this skin condition might be a newly recognized side effect of the combination therapy.
Objective: To identify discrepancies in influenza, Tdap, and COVID-19 vaccine uptake and offer rates among pregnant individuals across various social determinants of health including race, ethnicity, foreign-born status, education level, and health insurance coverage, highlighting potential interventions to improve vaccine uptake in pregnancy.
Methods: An IRB-approved cross-sectional survey was conducted on the postpartum floor of a large urban hospital in South Florida. Between July to September 2021, 359 participants consented and answered questions on their demographics, social background, and influenza, Tdap, and COVID-19 vaccine history.
Our objective was to examine the educational, research, and leadership trends among gynecologic oncology (GYO) fellowship program directors (PD) and how these vary by gender. PDs were identified using the Society of Gynecologic Oncology Fellowship Directory. Surveys were sent to PDs' emails to obtain information about demographics, education, and research background.
View Article and Find Full Text PDFObjective: To assess provider attitudes and practices regarding vaccination in pregnancy to discern strategies to increase vaccination rates in pregnancy, given that in the USA, various healthcare organizations recommend that pregnant individuals be vaccinated against influenza, pertussis, and SARS-CoV-2, but vaccination rates among gravidas remain suboptimal across these vaccines.
Methods: An Institutional Review Board-approved survey was disseminated to obstetric healthcare providers by email from June through October 2021. Questions assessed provider demographics, attitudes, and practices surrounding vaccination in pregnancy.